Loading…
Proto Labs, Inc.
NYSE: PRLB Industrials Metals 🔎 Screen
🏹 Trader: 🚀 Stage 2 + Near High 📈 Stage 2 🎯 Near 52W High | BRS 65 Forming View all →
📈 Stage 2 detected Find the fundamental catalyst → → run Growth Triggers in Ask AI
$1.9B
Market Cap
57.5
P/E
1.15
PEG
3.1%
ROCE
3.2%
ROE
0.00
D/E
4.7%
OPM
-16.8%
% from 52W High
76
α RS
🔍 PRLB is showing a notable setup because RS Rating is 76 and an ECS of 53.9 last quarter. Net: Partial signal stack, not a recommendation. ? RS Rating ECS
Sources
RS Rating 76 · ECS 53.9
⚖️ Compare 🔒 Generate Report 🔒 Research Packet 📚 Guides
🌏 Global Investor Returns
Currency-adjusted total returns for PRLB including FX impact
🌏
Click 🌏 Returns tab to load data
📈 Price History
Ratio Health
Excellent
Good
Average
Poor
By Category
📊 Sector Averages
About

Proto Labs, Inc., together with its subsidiaries, operates as a digital manufacturer of custom parts in the United States and Europe.

Key Ratios Snapshot
📈 Growth Pattern
📊 Quick Scorecard
Loading…
⭐ Superinvestors Holding PRLB
View All Superinvestors →
Manager Shares Value % of Fund Period
Jim Simons Renaissance Technologies LLC 520.3K $29.7M 0.05% Mar 2026
Cathie Wood ARK Investment Management 45.7K $2.6M 0.02% Mar 2026
Steve Cohen Point72 Asset Management 32.4K $1.8M 0.00% Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
🎙 Management Tone Confident Specific ↑ Improving 4 quarters Full tone analysis in Intelligence →
📊 MIXED Protolabs Q1 2026: Record revenue $139.3M (+10.4% YoY), highest non-GAAP EPS in 5 years
Revenue & Profitability
Revenue $139.3M, up 10.4% YoY. Non-GAAP gross margin 46.2% (up 140 bps). Adjusted operating expenses 35.1% of revenue (down 220 bps). Adjusted EBITDA $22.8M (16.3% of revenue). Non-GAAP EPS $0.54 (highest in over 5 years). Cash from operations $17.5M. Cash and investments $158M, zero debt.
Outlook
Management sees strong demand in aerospace/defense (space exploration, satellites, drones) and robotics. Full-year 2026 revenue growth guidance maintained at 6%-8%, with Q2 revenue expected between $140M-$148M (midpoint implies 7% YoY growth). Macro uncertainty was cited for conservatism despite a strong Q1. Normal seasonality: Q2 up sequentially, Q3 flat to slightly up, Q4 down due to holidays.
Growth Drivers
Key growth levers: larger strategic customers (revenue per customer +20% YoY), CNC machining (US +23% YoY), and aerospace/defense verticals. Injection molding benefited from larger production orders early in the life cycle. Metal 3D printing (DMLS) grew nearly 30% in the US. Europe showed early recovery with 11% sequential growth. Computer/electronics and industrial/commercial machinery also performed well.
Balance Sheet & CapEx
Capital investments include adding CNC mills and DMLS metal 3D printers to address capacity constraints. Operating expense increases will fund R&D and software development for strategic pillars. The company has $158M in cash and investments to support these initiatives. No specific CapEx guidance was provided.
Margins
Non-GAAP gross margin was 46.2% (up 140 bps YoY and sequentially), driven by volume, pricing actions, and favorable mix (factory vs. network). Full-year gross margin expected slightly up. Second quarter gross margin flat to slightly down sequentially. OpEx is expected to increase quarter-over-quarter as investments in R&D and software development ramp. Adjusted EBITDA margin expanded to 16.3%.
Key Risks
Management flagged macro uncertainty as a reason for conservative full-year guidance. Weakness in 3D printing network demand was noted (especially in Europe). Europe declined 3.4% in constant currency year-over-year, though improving sequentially. Dependency on execution of strategic initiatives (production expansion, lean management) and customer adoption of production services.
Generated by AI · Q1 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter
🔍
🔎 See cross-company document search → ?
📞 Earnings Call Transcripts (5)
Q2 2026 Q2 2026 2026-07-31
Record quarterly revenue and profitability driven by double-digit growth in CNC Machining and Injection Molding, with strong demand from aerospace, defense, and medical sectors. Europe showed early signs of turnaround, and full-year revenue growth outlook was raised to 8%-10%.
Q1 2026 Q1 2026 2026-05-01
Record Q1 revenue and EPS were driven by strong U.S. growth, CNC machining, and large strategic customers, with margin expansion and robust cash generation. Guidance remains conservative due to macro uncertainty, but investments in innovation and production are accelerating.
Q4 2025 Q4 2025 2026-02-06
Record Q4 and full-year 2025 revenue driven by double-digit U.S. growth and strong CNC demand. 2026 is set for transformation, with 6%-8% revenue growth expected and strategic initiatives targeting innovation, production expansion, and operational efficiency.
Q3 2025 Q3 2025 2025-10-31
Record Q3 revenue and earnings exceeded expectations, driven by strong U.S. CNC machining and sheet metal demand, with notable growth in aerospace, defense, and robotics. Gross margin and EBITDA improved sequentially, and Q4 guidance implies continued year-over-year growth.
Q2 2025 Q2 2025 2025-07-31
Record Q2 revenue and EPS exceeded guidance, driven by strong CNC machining and aerospace/defense demand. Margins were pressured by tariffs but recovered by June; cash flow and share repurchases remained robust. Q3 outlook projects continued growth and typical Q4 seasonality.
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, ECS update, earnings-call, and SEC announcement for this company — in one chronological lane.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

Financial Model
Projections are built from each company's audited annual financials (Income Statement, Balance Sheet, Cash Flow) over the last 5 fiscal years. Forward assumptions — revenue growth %, EBITDA margin, D&A (USD millions), interest expense, tax rate, and capex — are AI-generated using historical context and refreshed twice a year: after the December results season and after the September/Q4 results season.

DCF Valuation
Fair Value = Σ(FCFt / (1+WACC)t) + Terminal Value. Terminal Value uses the Gordon Growth Model: FCF5 × (1+g) / (WACC−g). Default WACC: 10% (US risk-free ~4.5%, equity risk premium ~5.5%). Default terminal growth: 3% (long-run US nominal GDP proxy).

CAGR Tracker
Expected 5-year CAGR = (DCF Fair Value / Current Price)1/5 − 1. Assumes fair value is reached in exactly 5 years — a mechanical estimate only.

Data Sources & Limitations
Financial statements sourced from public filings. Prices updated daily. Forward assumptions are AI-generated. All monetary values in USD millions. Non-US ADR companies may have currency conversion inaccuracies. Models are point-in-time and do not update intra-quarter or account for M&A, macro shocks, or extraordinary items.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.